Milford, Massachusetts -– SeraCare Life Sciences, a provider of high quality

biological materials that help optimize diagnostic performance, reliability, and repeatability

across the IVD lifecycle, today announced four new research panels that deliver hard-to-find

material for Hepatitis C (HCV), Chagas and Dengue.

“Our customers rely on SeraCare to provide the disease materials they need to troubleshoot,

challenge, and validate their assays,” said Kim Anderson, product manager at SeraCare Life

Sciences. “SeraCare’s strong global sourcing network enables us to deliver the precise

materials our customers require. Our new Worldwide HCV panel is particularly exciting as it

delivers a substantial breadth of genotypes with multiple donor samples.”

Hepatitis C (HCV) Performance Panel

SeraCare’s new Worldwide Hepatitis C (HCV) AccuSet™ Performance Panel is a 20-member

panel of undiluted, naturally occurring plasma samples. Panel members represent bleeds from

multiple individuals positive for HCV from varying countries of origin. This panel of human

plasma samples demonstrates a diverse collection of HCV genotypes 1, 2, 3, 4, 5, and 6 with

varying subtypes. Test results from commercially-available HCV genotype, RNA, and antibody

assays are included for characterization of the panel members.

Chagas Seroconversion and Performance Panels

Well-characterized Chagas samples are essential to support development, evaluation,

validation, and regulatory submissions for Chagas assays. SeraCare today introduced two new

Chagas panels:

The Chagas (T. cruzi) AccuVert™ Seroconversion Panel, a 10-member panel of undiluted,

naturally occurring plasma samples, is the first of its kind in the market. This rare and uniquepanel represents serial bleeds collected over the course of 118 days from a single individual

during the development of a Chagas infection and subsequent response.

The Chagas (T. cruzi) Mixed Titer AccuSet™ Performance Panel is a 21-member panel of

undiluted, naturally occurring plasma samples. Panel members represent bleeds from multiple

individuals positive for Chagas disease from varying countries of origin.

Dengue Early Infection Performance Panel

The new Dengue Early Infection AccuSet™ Performance Panel is a 6-member panel of

undiluted, naturally occurring plasma samples. Panel members represent serial bleeds collected

over the course of 14 days from a single individual during the development of a Dengue

infection and subsequent response. Test results from commercially-available Dengue assays

are included for characterization of the panel members. This panel of human plasma samples is

positive for Dengue RNA, NS1 antigen, and IgM and IgG antibodies. SeraCare’s new panels are available immediately worldwide. For more information, contact

SeraCare Customer Service at +1 508-244-6400 / 1-800-676-1881 or visit www.seracare.com. About SeraCare Life Sciences, Inc.

SeraCare partners with diagnostics researchers, IVD manufacturers, and clinical laboratories to

shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN® quality

controls, research panels, KPL™ antibodies and immunoassay reagents, SeraCon™ processed

plasma, specialty human blood products, and characterized disease state materials. SeraCare

helps bridge the gap between today’s diagnostic solutions and tomorrow’s emerging

technologies. For more information, visit www.seracare.com.